ABLYNX NV/ADR (NASDAQ:ABLX) and Acceleron Pharma (NASDAQ:XLRN) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Analyst Recommendations

This is a breakdown of recent ratings for ABLYNX NV/ADR and Acceleron Pharma, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ABLYNX NV/ADR 0 0 0 0 N/A
Acceleron Pharma 0 3 5 0 2.63

Acceleron Pharma has a consensus target price of $60.63, suggesting a potential upside of 37.28%. Given Acceleron Pharma’s higher probable upside, analysts clearly believe Acceleron Pharma is more favorable than ABLYNX NV/ADR.

Valuation and Earnings

This table compares ABLYNX NV/ADR and Acceleron Pharma’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ABLYNX NV/ADR N/A N/A N/A N/A N/A
Acceleron Pharma $13.99 million 163.16 -$118.87 million ($2.59) -17.05

ABLYNX NV/ADR has higher earnings, but lower revenue than Acceleron Pharma.

Profitability

This table compares ABLYNX NV/ADR and Acceleron Pharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ABLYNX NV/ADR N/A N/A N/A
Acceleron Pharma -849.62% -36.63% -34.59%

Insider and Institutional Ownership

86.1% of Acceleron Pharma shares are held by institutional investors. 3.0% of Acceleron Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Acceleron Pharma beats ABLYNX NV/ADR on 5 of the 8 factors compared between the two stocks.

ABLYNX NV/ADR Company Profile

Ablynx NV, a late-stage clinical biopharmaceutical company, develops treatments for a range of therapeutic indications. The company develops Nanobodies that are proprietary therapeutic proteins based on single-domain antibody fragments for the treatment of inflammation, hematology, immuno-oncology, oncology, and respiratory diseases. Its clinical programs include caplacizumab, an anti-von Willebrand Factor Nanobody that has completed Phase III clinical trial to treat acquired thrombotic thrombocytopenic purpura; ALX-0171, which is in Phase IIb clinical trial for the treatment of respiratory syncytial virus infection; and Vobarilizumab, an anti-IL-6R Nanobody that has completed Phase IIb clinical trial for the treatment of rheumatoid arthritis, as well as in Phase II clinical trial to treat systemic lupus erythematosus. The company also develops ALX-0761, which is in Phase Ib clinical trial for the treatment of psoriasis, as well as various auto-immune disorders; Anti-VEGF/Ang2 Nanobody that is in Phase I clinical trial for patients with solid tumors; Anti-CX3CR1 Nanobody, which is in Phase I clinical trial for treating chronic kidney diseases; ozoralizumab, which has completed Phase I/IIa clinical trial for the treatment of auto-immune disorders with focus on rheumatoid arthritis; and ALX-0141, a trivalent Nanobody for the treatment of bone-loss related disorders comprising osteoporosis and bone metastasis, as well as completed a Phase I study in post-menopausal women. Ablynx NV has collaboration and alliance agreements with Merck & Co., Inc., AbbVie, Inc., Boehringer Ingelheim International GmbH, Merck KGaA, Eddingpharm, Novo Nordisk A/S, Novartis Pharma AG, Taisho Pharmaceutical Co., Ltd., and Sanofi S.A. The company was formerly known as MatchX and changed its name to Ablynx NV in June 2002. Ablynx NV was founded in 2001 and is headquartered in Ghent, Belgium.

Acceleron Pharma Company Profile

Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which is in Phase III clinical trials for the treatment of myelodysplastic syndromes and beta-thalassemia; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia and myelofibrosis. The company is also developing and sotatercept for the treatment of patients with pulmonary arterial hypertension. In addition, the company is developing ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with facioscapulohumeral dystrophy and Charcot-Marie-Tooth disease; and ACE-2494, which is in Phase I clinical trials for the treatment of systemic muscle disorders. It has a collaboration, license, and option agreement with Celgene Corporation. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings for ABLYNX NV/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABLYNX NV/ADR and related companies with MarketBeat.com's FREE daily email newsletter.